Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.

This case report describes a rare instance of Vogt-Koyanagi-Harada disease in a 21-year-old Asian woman, highlighting unusual oral manifestations such as tooth discoloration and misalignment, which expand the known clinical spectrum of the disorder.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study found that blood samples from donors on teratogenic drugs sometimes exceeded recommended concentration limits, suggesting a need for improved deferral policies.

This article presents a collection of 70 multiple choice questions designed to assist haematology and core medical trainees with diagnostic and management skills, but it provides no new clinical findings.

This study presented a case of a Labrador Retriever with recurrent skin lesions and confirmed vitamin A-responsive dermatosis after successful treatment with vitamin A therapy, highlighting the importance of considering vitamin A deficiency in primary keratinization disorders.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.

This study found that topical Vorinostat induced significant hair regrowth in mice with alopecia areata, suggesting it as a potential repurposable treatment for the condition.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

New ABCA12 gene mutations were linked to a skin condition with scaling and hair loss, and a treatment helped with hair loss in a related case.

Light therapy can effectively treat vitiligo and hair loss caused by a specific medication.

This case report highlights a patient who developed pancytopenia, transaminase elevation, and alopecia after consuming large amounts of veterinary albendazole purchased online, which he used without medical supervision.

This study found that deleting β-catenin in epidermis-specific VDR knockout mice did not prevent UVB-induced skin tumors, indicating β-catenin does not compensate for VDR's role in tumor suppression.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

In this study, researchers found that BST2 expression is significantly upregulated in skin sections of mice with alopecia areata, implicating BST2's role in the disease pathogenesis through the action of epidermal γδ T cells and macrophages.

This study in mutant mice found that Bmpr2 and Acvr2a are individually redundant, but together essential for normal hair follicle development, with their reduction causing rapid hair cycling and graying.

This research successfully established a novel mouse model for anagen effluvium using BrdU treatment, which induced hair loss and pathological changes mimicking human symptoms.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

This report documents a case where a healthy female developed alopecia universalis after receiving the 9-valent HPV vaccine, highlighting the potential for autoimmune reactions and the importance of prompt medical attention.

This study found that the rs2228570 polymorphism of the VDR gene was associated with an increased risk of melanoma, while the rs731236 polymorphism was linked to a protective effect against the disease in Colombian patients.

This review of the JEADV editorial report highlights the journal's significant growth in submissions, quality, and impact over the course of the pandemic, but offers no new research findings.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study found that 4-(4-Phenoxybenzoyl)benzoic acid derivatives may act as antioxidants by scavenging certain reactive oxygen species but exhibit prooxidant behavior under specific conditions.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.